Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...
Hosted on MSN2mon
25-Year-Old Shares Subtle Lymphoma Symptoms That Were MisdiagnosedJace Yawnick was diagnosed with primary mediastinal B-cell non-Hodgkin lymphoma in Jan. 2024 at 25 years old. However, Yawnick's first onset of symptoms dates back to Aug. 2023, when he was ...
Dan Evans, 19, from Newark in Nottinghamshire, described his huge relief ringing the "cancer-free bell" at the teenage cancer ward at Nottingham City Hospital. Mr Evans underwent a successful stem ...
Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, ...
Yescarta (axicabtagene ciloleucel) has been approved as a treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma ...
The direct antiglobulin test was positive for anti-C3d specificity, with cold agglutinin titer confirming the diagnosis of CAD.
The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...
A 19-year-old is celebrating being cancer-free – a year after he was told that there was no hope and to “go home and make memories with his family”.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback